Latest Breaking News On - ஜேசன் அசாத் - Page 8 : comparemela.com

Message : Required fields BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company ), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten public offering of 1,807,143 shares of its common stock, offered at a price of $7.00 to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 271,071 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being offered by the Company. The offering is expected to close on or about March 16, 2021, subject to customary closing conditions. The gross proceeds to the Company from this offering are expected to be approximately $12.65 million, before deducting underwriting discounts and commissions and other estimated offering expenses payab

New yorkUnited statesPaul mcbarronJason assadExchange commissionSyndicate prospectus departmentCyclacel pharmaceuticals incArcadia securitiesThalmann coOppenheimer coCapital partnersCapital marketsCyclacel pharmaceuticalsAnnual reportAll rightsInc stock exchange